{
    "clinical_study": {
        "@rank": "11642", 
        "arm_group": [
            {
                "arm_group_label": "besifovir 150mg", 
                "arm_group_type": "Experimental", 
                "description": "Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d."
            }, 
            {
                "arm_group_label": "Tenofovir 300mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d."
            }
        ], 
        "brief_summary": {
            "textblock": "To prove that a study drug is noninferior to a control drug with a proportion of subjects\n      who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week  after\n      48-week administration of Besifovir 150 mg, or Tenofovir 300 mg as a control drug to chronic\n      hepatitis B patients"
        }, 
        "brief_title": "Phase 3 Study of Besifovir", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Screening Period Subject registration is conducted with confirming selection and\n           exclusion criteria after a written consent form is obtained within 28 days before\n           clinical trial drug administration.\n\n        -  Wash-out Period Subjects who had been treated with antiviral agents within 12 weeks\n           should complete a 4-week wash-out period from the stage of stopping antiviral agent\n           treatment before a baseline visit and subjects who have no experience of antiviral\n           agent treatment start a baseline visit without a wash-out period.\n\n        -  Baseline Subjects who visit on the date of starting clinical trial drug administration\n           are randomized to a test group or a control group at a ratio of 1:1. Double blindness\n           is applied for both groups.\n\n        -  Treatment period Subjects are orally administered with a clinical trial drug q.ds.i.d.\n           for 48 weeks and visit at the 0, 4th, 12th, 24th, 36th, and 48th week for an HBV DNA\n           test, laboratory tests, a physical test, vital signs, and adverse events.\n\n        -  Follow-up period Subjects are provided with appropriate treatment after completing the\n           48-week trial or dropping out. Subjects visit once at the 60th week for follow-up of\n           adverse events, such as acute deterioration of hepatitis B, and HBV DNA test results.\n           If any treatment is not conducted after 48-week administration, subjects visit at\n           intervals of four weeks until a follow-up visit (60th week) and the same tests with the\n           24th week visit (Visit 5) are conducted. However, subjects who participate in a 48-week\n           separate extended trial conducted after 48-week administration in this clinical trial\n           do not have a follow-up period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients over the age of 20 years old\n\n          2. Patients who show positive HBsAg or has a history of chronic hepatitis B for the last\n             six months or more before screening\n\n          3. Patients who have not received interferon (including Pegylation formulation) to treat\n             chronic hepatitis and antiviral agents for more than 12 weeks.\n\n          4. Patients who showed positive HBsAg during screening\n\n          5. Patients who showed HBV DNA measured by COBAS TaqManTM HBV Test more than 1x105\n             copies/mL (17,241 IU/mL) in case of positive HBeAg during screening, or who showed\n             HBV DNA measured by COBAS TaqManTM HBV Test more than 1x104 copies/mL (1,724 IU/mL)\n             in case of negative HBeAg\n\n          6. Patients who showed ALT more than 1.2 times, or less than 10 times of the upper limit\n             in the normal range during screening\n\n          7. Patients who were explained about the purpose, methods and effects of the clinical\n             trial and then, signed a written consent form.\n\n          8. Male and female patients of childbearing age who can use double contraception\n             acknowledged* during a trial period * Double contraception acknowledged means\n             combination of barrier contraception (condom, diaphragm, etc.) and other\n             contraception (sterilization operation, intrauterine contraceptive device, oral\n             contraceptive drug, other hormone delivery system, contraceptive cream, jelly or\n             foam, etc.).\n\n        Exclusion Criteria:\n\n          1. Patients who have hepatitis C (HCV), hepatitis D (HDV), or human immunodeficiency\n             virus (HIV)\n\n          2. Patients with a uncompensated liver disease who have at least one of the following\n             values or signs during screening\n\n               -  Total bilirubin > 2 x ULN\n\n               -  Prothrombin time delayed more than three seconds compared to the normal value\n\n               -  Serum Albumin < 30 g/L (3 g/dL)\n\n               -  A medical history of ascites, jaundice, hemorrhage by varix, hepatic\n                  encephalopathy, or other signs of liver function loss\n\n          3. At least one of the following laboratory values during screening\n\n               -  Hemoglobin < 9.0 g/dL\n\n               -  Absolute neutrophil count (ANC) < 1.5 x 109 /L (1500 /mm3)\n\n               -  Platelet count < 100 x 109 /L (100 x 103 /mm3)\n\n               -  Serum creatinine > 1.5 mg/dL\n\n               -  Serum amylase > 2 x ULN and Lipase > 2 x ULN\n\n          4. Patients who showed GFR less than 50 mL/min by calculating MDRD (Modification of Diet\n             in Renal Disease: 1.86 x PCr -1.154 x AGE -0.203 (x 0.742 for women)) during\n             screening\n\n          5. Patients who showed alpha-fetoprotein(AFP) more than 50 ng/mL during screening and\n             are estimated to have hepatocellular carcinoma (HCC) through liver/abdomen CT scans\n\n          6. Patients who had received the following drugs for the last two months before\n             screening (however, short-term use (less than consecutive 14 days) of these drugs and\n             low-dose aspirin (100 mg, maximally, 300 mg/day) are allowed.)\n\n               -  Nephrotoxic drugs (e.g. Aminoglycosides, Amphotericin B, NSAIDs)\n\n               -  Hepatotoxic drugs (e.g. Erythromycin, Ketoconazole, Rifampin, Fluconazole,\n                  Dapsone)\n\n               -  Anticoagulant (e.g. Warfarin)\n\n          7. Patients who are suspected by an investigator to have the level of immunity decreased\n             among patients who had been administered with immunosuppressants within six months\n             before screening\n\n          8. Patients who had been administered with long-term general corticosteroids (more than\n             consecutive 14 days) at a high dose (more than prednisolone 20 mg daily*) within\n             three months before screening (In case of local corticosteroids, an investigator\n             decides it.)\n\n             * It is equal to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg,\n             methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, betamethasone 2.4\n             mg.\n\n          9. Patients who were diagnosed as a malignant tumor within five years before screening\n             or have a relapse of a malignant tumor (In case of a benign tumor, if an investigator\n             decides that it does not affect the progress of the clinical trial during a trial\n             period, the patients can be registered.)\n\n         10. Patients who are scheduled to participate in other clinical trial after registered in\n             this clinical trial, or had been participated in other clinical trial within three\n             months before registered in this clinical trial\n\n         11. Pregnant women, lactating women, or patients who planned pregnancy during a trial\n             period\n\n         12. Patients who have hypersensitivity to the clinical trial drug in this clinical trial\n\n         13. Patients who have a past medical history of clinical alcohol or drug abuse within a\n             year before screening or now are abusers\n\n         14. Patients who have a severe disease, such as liver diseases, heart failure, renal\n             failure, and pancreatitis, decided by an investigator to have an effect on this\n             clinical trial\n\n         15. Patients who have other hepatic diseases (hematochromatosis, Wilson's disease,\n             alcoholic liver diseases, nonalcoholic steatohepatitis, \u03b11-antitrypsin deficiency)\n             except hepatitis B\n\n         16. Patients who received an organ transplant\n\n         17. Persons who are possible to decline daily function due to a mental disease or\n             patients who are not able to understand the purpose and methods of this clinical\n             trial\n\n         18. Patients who are decided by an investigator as unsuitable for conducting this\n             clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "188", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937806", 
            "org_study_id": "ID_BVCL011"
        }, 
        "intervention": [
            {
                "arm_group_label": "besifovir 150mg", 
                "description": "Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.", 
                "intervention_name": "besifovir 150mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tenofovir 300mg", 
                "description": "Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.", 
                "intervention_name": "tenofovir 300mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chronic hepatitis B", 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Hong Soo Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Cheonan", 
                        "country": "Korea, Republic of", 
                        "state": "Chungchoengnam-do"
                    }, 
                    "name": "Soonchunhyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Hong Soo Kim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dong Joon Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "ChunCheon", 
                        "country": "Korea, Republic of", 
                        "state": "Kangwon-do"
                    }, 
                    "name": "Hallym University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Dong Joon Kim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Moon Young Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Wonju", 
                        "country": "Korea, Republic of", 
                        "state": "Kangwon-do"
                    }, 
                    "name": "Wonju Sevrerance Christian Hospital"
                }, 
                "investigator": {
                    "last_name": "Moon Young Kim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hyung Joon Yim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Ansan", 
                        "country": "Korea, Republic of", 
                        "state": "Kyounggi-do"
                    }, 
                    "name": "Korea University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Hyung Joon Yim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joo Hyun Sohn, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Guri", 
                        "country": "Korea, Republic of", 
                        "state": "Kyunggi-do"
                    }, 
                    "name": "Hanyang University Guri Hospital"
                }, 
                "investigator": {
                    "last_name": "Joo Hyun Sohn, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jae-Youn Cheong, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Suwon,", 
                        "country": "Korea, Republic of", 
                        "state": "Kyunggi-do"
                    }, 
                    "name": "Ajou University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jae-Youn Cheong, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Young Oh Kweon, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyungpook National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Young Oh Kweon, M.D.,Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Byung Seok Lee, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chungnam National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Byung Seok Lee, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jin-Woo Lee, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inha University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jin-Woo Lee, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sung Jae Park, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Pusan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inje University Busan Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Sung Jae Park, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "JinMo Yang, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "The Catholic University of Korea, Seoul St. Vincent's Hospital"
                }, 
                "investigator": {
                    "last_name": "JinMo Yang, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Young-Suk Lim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Young-Suk Lim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yoon Jun Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Yoon Jun Kim, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kwan Sik Lee, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Gangnam Severance Hospital"
                }, 
                "investigator": {
                    "last_name": "Kwan Sik Lee, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jang, Jae Young, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Soonchunhyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jae Young Jang, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kwang-Hyub Han, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Severance Hospital of Yonsei University"
                }, 
                "investigator": {
                    "last_name": "Kwang-Hyub Han, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Seung Kew Yoon, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "The Catholic University of Korea, Seoul St. Mary's Hospital"
                }, 
                "investigator": {
                    "last_name": "Seung Kew Yoon, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Won Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Boramae medical Center"
                }, 
                "investigator": {
                    "last_name": "Won Kim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Soon Ho Um , M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Soon Ho Um, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Neung Hwa Park, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Ulsan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Ulsan University Hospital,"
                }, 
                "investigator": {
                    "last_name": "Neung Hwa Park, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase \u2162, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks", 
        "overall_contact": {
            "email": "trpv1@ildong.com", 
            "last_name": "Se-Eun Kim, Master", 
            "phone": "82(0)2 526 3518"
        }, 
        "overall_contact_backup": {
            "email": "gyhong@ildong.com", 
            "last_name": "gayou Hong, Bechelor", 
            "phone": "82(0)2 526 3519"
        }, 
        "overall_official": [
            {
                "affiliation": "Kangnam Severance Hospital, Yonsei University, Seoul, Korea, Republic of", 
                "last_name": "Kwan Sik Lee, M.d., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyungpook National University Hospital, Seoul, Korea, Republic of", 
                "last_name": "Young Oh Kweon, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Medical Center, Ansan, Kyunggi-do, Korea, Republic of", 
                "last_name": "Hyung Joon Yim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Medical Center, Seoul, Korea, Republic of", 
                "last_name": "Soon Ho Um, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Boramae medical Center, Seoul, Korea, Republic of", 
                "last_name": "Won Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University Busan Paik Hospital, Pusan, Korea, Republic of", 
                "last_name": "Sung Jae Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital, Seoul, Korea, Republic of", 
                "last_name": "Yoon Jun Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of", 
                "last_name": "Yoon Jun Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center, Seoul, Korea, Republic of", 
                "last_name": "Young-Suk Lim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea, Seoul St. Vincent's Hospital, Seoul, Korea, Republic of", 
                "last_name": "JinMo Yang, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Soonchunhyang University Hospital, Seoul, Korea, Republic of", 
                "last_name": "Jang, Jae Young, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ajou University Medical Center, Suwon, Kyunggi-do, Korea, Republic of", 
                "last_name": "Jae-Youn Cheong, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ulsan University Hospital, Ulsan, Korea, Republic of", 
                "last_name": "Neung Hwa Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wonju Sevrerance Christian Hospital, Wonju, Kangwon-do,  Republic of", 
                "last_name": "Moon Young Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inha University Hospital, Incheon, Inchen, Korea, Republic of", 
                "last_name": "Jin-Woo Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hallym University Medical Center, ChunCheon, Kangwon-do, Korea, Republic of", 
                "last_name": "Dong Joon Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chungnam National University Hospital, Daejeon, Korea, Republic of", 
                "last_name": "Byung Seok Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanyang University Guri Hospital, Guri, Kyunggi-do, Korea, Republic of", 
                "last_name": "Joo Hyun Sohn, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Severance Hospital of Yonsei University, Seoul, Korea, Republic of", 
                "last_name": "Kwang-Hyub Han, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Soonchunhyang University Hospital, Choenan, Chungchoengnam-do, Korea, Republic of", 
                "last_name": "Hong Soo Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea, Republic of : Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week", 
            "safety_issue": "No", 
            "time_frame": "at the 48th week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937806"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The rate of subjects who showed HBV DNA less than 116 copies/mL (20 IU/mL, LOQ of COBAS TaqManTM) at the 48th week", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "Average amount of change in an HBV DNA common logarithm value at the 48th week to a base value", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed ALT normalized at the 48th week", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and ALT normalized at the 48th week", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed HBsAg serum loss and/or seroconversion (HBsAg loss and Anti-HBs formation) at the 48th week", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed HBeAg serum loss and/or seroconversion (HBeAg loss and Anti-HBe formation) at the 48th week among subjects with positive HBeAg", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and HBeAg loss at the 48th week among subjects with positive HBeAg", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and HBeAg seroconversion at the 48th week among subjects with positive HBeAg", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "Changes in antiviral drug resistant mutation according to HBV DNA sequencing results at the 48th week", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }, 
            {
                "measure": "The rate of subjects who showed virologic breakthrough according to serum HBV DNA at the 48th week", 
                "safety_issue": "No", 
                "time_frame": "at the 48th week"
            }
        ], 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}